TCL Archive Oregon Center Launching $1 Billion Program To Identify Lethal Cancers Before They Kill May 9, 2014
TCL Archive An “insurgency” targets randomized trials, demands access to investigational drugs. August 5, 2005
TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004
TCL Archive FDA Considering Ways To Improve Process Of Secondary Approvals Of Cancer Drugs November 1, 1991
TCL Archive Money Earmarked for WVU Center Could Be Returned To Treasury; BYRD Get Assurances From DeVita May 31, 1985
